Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the ...

Parnassus Core Equity Fund sees Eli Lilly And Co. (NYSE:LLY) as a strong long-term investment due to its GLP-1 franchise and ...

We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at ...

Lilly makes tirzepatide, commercialized under the name Zepbound for weight loss and Mounjaro ... or is Lilly stock still a buy? Let's find out. So, first let's talk about the Eli Lilly story ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares leaving ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Eli Lilly stock has advanced more than 200% over the ... commercialized under the name Zepbound for weight loss and Mounjaro for type 2 diabetes. But doctors have prescribed either one for ...

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ...